Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
8.50
+0.38 (4.68%)
Oct 19, 2026, 1:07 PM EDT - Market open
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $4.00K in the quarter ending June 30, 2026, a decrease of -50.00%. This brings the company's total for the last twelve months to $27.00K, down -55.00% year-over-year. In the year 2025, Lyell Immunopharma had annual revenue of $36.00K, down -40.98%. That makes Lyell Immunopharma the 46,891st largest company in the world by revenue and 7,061st in the United States.
Revenue (ttm)
$27.00K
Revenue Growth
-55.00%
P/S Ratio
7,369.69
Revenue / Employee
$168
Employees
161
Market Cap
208.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.00K | -25.00K | -40.98% |
| Dec 31, 2024 | 61.00K | -69.00K | -53.08% |
| Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
| Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
| Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
| Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
| Dec 31, 2019 | 657.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Protalix BioTherapeutics | 80.62M |
| Zentalis Pharmaceuticals | 26.87M |
| Alector | 13.86M |
| Pyxis Oncology | 11.04M |
| Evommune | 10.00M |
| Camp4 Therapeutics | 4.22M |
| Sol-Gel Technologies | 1.80M |
LYEL News
- 4 weeks ago - Lyell Immunopharma Transcript: 2026 Global Healthcare Conference - Transcripts
- 5 weeks ago - Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer - GlobeNewsWire
- 2 months ago - Lyell Immunopharma reports Q2 net loss ($44.8M) vs. ($42.7M) last year - TheFly
- 2 months ago - Lyell Immunopharma Quarterly report: Q2 2026 - Filings
- 2 months ago - Lyell Immunopharma Earnings release: Q2 2026 - Filings
- 2 months ago - Lyell Immunopharma Slides: Company presentation - Filings
- 2 months ago - Lyell Immunopharma initiated with a Buy at Stifel - TheFly